THERAPY DOSSIER · th-2b0f2e8388ef

Recombinant Emc10 (mouse homologue of EMC10)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28931551 ↗2017Reported benefit

EMC10 (Endoplasmic Reticulum Membrane Protein Complex Subunit 10) Is a Bone Marrow-Derived Angiogenic Growth Factor Promoting Tissue Repair After Myocardial Infarction.

MixedIschaemia-reperfusionCardiacWild-type, Emc10-deficient and bone marrow chimeric mice; heart failure-prone FVB/N mice used for recombinant protein therapyOsmotic minipump deliveryAfter myocardial infarction

Model: Myocardial infarction induced by transient coronary artery ligation

Emc10 knockout mice showed impaired infarct border zone capillarisation, larger infarct scars and more pronounced left ventricular remodelling than wild-type mice, and transplantation with wild-type bone marrow rescued the angiogenic defect. Treatment of FVB/N mice with recombinant Emc10 enhanced i…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…